Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
11 2020
Historique:
received: 23 03 2020
revised: 11 06 2020
accepted: 15 06 2020
pubmed: 14 8 2020
medline: 11 11 2021
entrez: 14 8 2020
Statut: ppublish

Résumé

The International Cancer Benchmarking Partnership demonstrated international differences in ovarian cancer survival, particularly for women aged 65-74 with advanced disease. These findings suggest differences in treatment could be contributing to survival disparities. To compare clinical practice guidelines and patterns of care across seven high-income countries. A comparison of guidelines was performed and validated by a clinical working group. To explore clinical practice, a patterns of care survey was developed. A questionnaire regarding management and potential health system-related barriers to providing treatment was emailed to gynecological specialists. Guideline and survey results were crudely compared with 3-year survival by 'distant' stage using Spearman's rho. Twenty-seven guidelines were compared, and 119 clinicians completed the survey. Guideline-related measures varied between countries but did not correlate with survival internationally. Guidelines were consistent for surgical recommendations of either primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery with the aim of complete cytoreduction. Reported patterns of surgical care varied internationally, including for rates of primary versus interval debulking, extensive/'ultra-radical' surgery, and perceived barriers to optimal cytoreduction. Comparison showed that willingness to undertake extensive surgery correlated with survival across countries (r Findings suggest international variations in ovarian cancer treatment. Characteristics relating to countries with higher stage-specific survival included higher reported rates of primary surgery; willingness to undertake extensive/ultra-radical procedures; greater access to high-cost drugs; and auditing.

Identifiants

pubmed: 32784203
pii: ijgc-2020-001403
doi: 10.1136/ijgc-2020-001403
pmc: PMC7656152
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1748-1756

Informations de copyright

© IGCS and ESGO 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Gynecol Oncol. 2012 Oct;127(1):75-82
pubmed: 22750127
Support Care Cancer. 2018 Oct;26(10):3507-3515
pubmed: 29696425
Int J Gynecol Cancer. 2016 Sep;26(7):1354-63
pubmed: 27648648
Jpn J Clin Oncol. 2019 Feb 1;49(2):137-145
pubmed: 30521037
Lancet Oncol. 2019 Nov;20(11):1493-1505
pubmed: 31521509
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Gynecol Oncol. 2013 Sep;130(3):493-8
pubmed: 23747291
Front Oncol. 2017 Aug 21;7:177
pubmed: 28871275
BMC Health Serv Res. 2018 May 9;18(1):342
pubmed: 29743065
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gynecol Oncol. 2020 Apr;157(1):234-244
pubmed: 32005583
J Clin Oncol. 2019 Jun 1;37(16):1380-1390
pubmed: 31002578
Gynecol Oncol. 2012 Aug;126(2):286-90
pubmed: 22507534
N Engl J Med. 2010 Sep 2;363(10):943-53
pubmed: 20818904
Eur J Public Health. 2016 Aug;26(4):538-42
pubmed: 26739995
Gynecol Oncol. 2015 Sep;138(3):700-6
pubmed: 25839910
Eur J Cancer. 2012 Jan;48(1):1-11
pubmed: 21741830
Ann Surg Oncol. 2019 Sep;26(9):2943-2951
pubmed: 31243666
BMC Cancer. 2008 Jan 29;8:31
pubmed: 18230177
Cancer. 2007 May 15;109(10):2031-42
pubmed: 17420977
Int J Gynecol Cancer. 2019 Jul;29(6):1032-1037
pubmed: 31263022
BMJ. 2019 Nov 27;367:l6326
pubmed: 31776110
Curr Oncol. 2018 Apr;25(2):119-125
pubmed: 29719427
Lancet. 2019 Dec 7;394(10214):2084-2095
pubmed: 31791688
Am Soc Clin Oncol Educ Book. 2016;35:143-51
pubmed: 27249695
N Z Med J. 2018 Jun 22;131(1477):45-55
pubmed: 29927915
Aust N Z J Obstet Gynaecol. 2017 Dec;57(6):585-587
pubmed: 29210052
Clin Epidemiol. 2016 Oct 25;8:485-490
pubmed: 27822089
Int J Gynecol Cancer. 2018 Jun;28(5):945-950
pubmed: 29664847
Int J Gynecol Cancer. 2012 Feb;22(2):226-31
pubmed: 22080889
Acta Oncol. 2016 Jun;55 Suppl 2:36-43
pubmed: 27355258
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Aust N Z J Obstet Gynaecol. 2017 Dec;57(6):651-658
pubmed: 28718942

Auteurs

Charles H Norell (CH)

International Cancer Benchmarking Partnership (ICBP), Policy & Information, Cancer Research UK, London, UK ICBP@cancer.org.uk.

John Butler (J)

International Cancer Benchmarking Partnership (ICBP), Policy & Information, Cancer Research UK, London, UK.
Gynaecology Department, Royal Marsden NHS Foundation Trust, London, UK.

Rhonda Farrell (R)

Gynaecological Oncology Department, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.

Alon Altman (A)

Department of Gynecologic Oncology, University of Manitoba, Winnipeg, Manitoba, Canada.

James Bentley (J)

Department of Obstetrics and Gynaecology, Dalhousie University, Halifax, Nova Scotia, Canada.

Citadel J Cabasag (CJ)

Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.

Paul A Cohen (PA)

Department of Gynaecological Oncology, St John of God Health Care, West Perth, Ontario, Australia.

Scott Fegan (S)

Department of Obstetrics and Gynaecology, NHS Lothian, Edinburgh, UK.

Michael Fung-Kee-Fung (M)

Department of Obstetrics, Gynaecology and Surgery, University of Ottawa, Ottawa, Ontario, Canada.

Charlie Gourley (C)

Cancer Research UK Edinburgh Centre, The University of Edinburgh, Edinburgh, Scotland, UK.

Neville F Hacker (NF)

Gynaecological Cancer Centre, Royal Hospital for Women, Randwick, New South Wales, Australia.
School of Women's & Children's Health, University of New South Wales, Sydney, New South Wales, Australia.

Louise Hanna (L)

Department of Oncology, Velindre Cancer Centre, Cardiff, Wales, UK.

Claus Kim Høgdall (CK)

Gynecologic Department, The Juliane Marie Centre, Copenhagen, Denmark.

Gunnar Kristensen (G)

Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.

Janice Kwon (J)

Department of Obstetrics and Gynaecology, Vancouver General Hospital, Vancouver, British Columbia, Canada.

Orla McNally (O)

Oncology and Dysplasia Service, Royal Women's Hospital, Parkville, Victoria, Australia.

Gregg Nelson (G)

Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.

Andy Nordin (A)

Department of Gynaecological Oncology, East Kent Hospitals University NHS Foundation Trust, Canterbury, UK.

Dearbhaile O'Donnell (D)

Department of Medical Oncology, St. James's Hospital, Dublin, Ireland.

Tine Schnack (T)

Department of Gynaecology, Copenhagen University Hospital, Copenhagen, Denmark.

Peter H Sykes (PH)

Department of Obstetrics and Gynaecology, University of Otago, Dunedin, New Zealand.

Ewa Zotow (E)

Policy & Information, Cancer Research UK, London, UK.

Samantha Harrison (S)

Policy & Information, Cancer Research UK, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH